ID: MRFR/Pharma/2259-HCR | February 2021 | Region: Global | 80 pages
Market Scenario
Global Intravenous Immunoglobulin (IVIg) Market is growing moderately. IVIg is concerned with the treatment of patients who have weak immune system. Human body produces enough antibodies to fight infection-causing germs, but if patients is suffering from immune deficiency then body can’t produce enough of them. The increasing demand for alternate immunoglobulin replacement therapies, new innovations, increasing R&D funding, developing healthcare infrastructure and increasing healthcare expenditure are major driving forces of the market. The Global Intravenous Immunoglobulin (IVIg) market is growing at a CAGR of 6.30% during the forecast period and expected to reach USD 10,485.86 Million by 2027.
Study objectives of Global Intravenous Immunoglobulin (IVIg) Market:
Global Intravenous Immunoglobulin (IVIg) Market, By Type
Sources: American Society of Health-System Pharmacists, WHO, national Health Service (NSH), Directorate of Industries, Annual report, White paper, Company Presentation
Intended Audience
Sources: American Society of Health-System Pharmacists, WHO, national Health Service (NSH), Directorate of Industries, Annual report, White paper, Company Presentation
Segments:
Global Intravenous Immunoglobulin (IVIg) Market has been segmented on the basis of type which comprise IgA (sub segments- IgA1 and IgA2), IgD, IgE, IgG,. On the basis of application it segmented into CIDP (Progressive, Recurrent, Monophasic), Hypogammaglobulinemia (sub segments- AGM1, AGM2, AGM3, AGM4, AGM5, AGM6), Multifocal Motor Neuropathy, Immunodeficiency diseases (sub segments- X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), severe combined immunodeficiency), Primary Humoral Immunodeficiency (Subsegments- B cell (antibody) deficiencies, T cell deficiencies, Combination B and T cell deficiencies, Defective phagocytes, Complement deficiencies, Unknown (idiopathic)), Myasthenia Gravis (Sub segments- generalized myasthenia gravis, ocular myasthenia gravis, Congenital myasthenia gravis, Transient neonatal myasthenia gravis), Guillain-Barre syndrome (Sub segments- Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), Miller Fisher syndrome (MFS), Acute motor axonal neuropathy (AMAN)and acute motor-sensory axonal neuropathy (AMSAN)), Kawasaki disease, ITP (Sub segments- acute and chronic), and others.
Regional Analysis of Global Intravenous Immunoglobulin (IVIg) Market:
Considering the global scenario of the market, North America is believed to be the largest market for Global IVIg. Moreover the European market, especially Western Europe is growing and second largest market for Global IVIg. On the other hand, Asia-Pacific is expected to grow at significant rate in the Global IVIg market during the forecasted period. Middle East and Africa is likely to have a limited but steady growth in the market, particularly market in North Africa is growing as compared to South and East region of Africa due to less awareness of these therapies and treatment.
Key Players for Global Intravenous Immunoglobulin (IVIg) Market:
Some of the key players in this market are: ABEONA THERAPEUTICS (US), Baxter (US), BDI Pharma (US), Biotest AG.(Germany),, China Biologic Products, Inc. (China), CSL Behring (US), Grifols Inc. (Spain), Kedrion S.p.A (us), Octapharma (Switzerland), Shire (Republic of Ireland), AND others. The report for Global Intravenous Immunoglobulin (IVIg) Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
Frequently Asked Questions (FAQ) :
Global Intravenous Immunoglobulin Market is projected to grow at a 6.30% CAGR between 2019-2027.
North America is predicted to lead the Intravenous Immunoglobulin Market.
Global Intravenous Immunoglobulin Market is predicted to touch USD 10,485.86 Million by 2027.
Developing healthcare infrastructure and rising healthcare expenditure is boosting market growth.
Specific strategies adopted by market players to create a foothold in the Intravenous Immunoglobulin market include extensive R&D, mergers, collaborations, and product launches.